Key Points
- OPKO CEO Phillip Md Et Al Frost bought 580,000 shares on November 21 at an average price of $1.33, a $771,400 purchase that increased his holding to 216,706,448 shares (a 0.27% increase), valued at about $288.2 million.
- Frost has been repeatedly buying shares recently (additional purchases of 580,000 on Nov. 19 at $1.31, 533,300 on Nov. 18 at $1.27, and 150,000 on Oct. 31 at $1.42), signaling continued insider accumulation totaling roughly 1.84 million shares across these trades.
- For context, OPKO trades around $1.32 with a market cap near $1.01 billion; the company recently beat EPS estimates ($0.03 vs. -$0.02) despite a 12.6% year-over-year revenue decline, and analysts' average rating is a Hold with an average target of $2.28.
OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost bought 580,000 shares of the firm's stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of $1.33 per share, for a total transaction of $771,400.00. Following the completion of the transaction, the chief executive officer owned 216,706,448 shares in the company, valued at $288,219,575.84. This represents a 0.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Phillip Md Et Al Frost also recently made the following trade(s):
- On Wednesday, November 19th, Phillip Md Et Al Frost purchased 580,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.31 per share, with a total value of $759,800.00.
- On Tuesday, November 18th, Phillip Md Et Al Frost acquired 533,300 shares of OPKO Health stock. The shares were bought at an average cost of $1.27 per share, for a total transaction of $677,291.00.
- On Friday, October 31st, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.42 per share, for a total transaction of $213,000.00.
OPKO Health Price Performance
Shares of OPK traded up $0.02 during mid-day trading on Friday, reaching $1.32. The company had a trading volume of 3,296,073 shares, compared to its average volume of 3,371,171. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02. The company has a market capitalization of $1.01 billion, a P/E ratio of -5.28 and a beta of 1.50. OPKO Health, Inc. has a twelve month low of $1.11 and a twelve month high of $2.04. The company's 50-day moving average is $1.44 and its 200-day moving average is $1.37.
OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.62% and a negative net margin of 28.10%.The firm had revenue of $151.67 million for the quarter, compared to analysts' expectations of $165.74 million. During the same period in the prior year, the business posted $0.03 earnings per share. The business's revenue was down 12.6% compared to the same quarter last year. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.
Institutional Trading of OPKO Health
A number of hedge funds and other institutional investors have recently modified their holdings of OPK. Brighton Jones LLC raised its position in OPKO Health by 29.1% in the 2nd quarter. Brighton Jones LLC now owns 38,916 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 8,775 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of OPKO Health by 4.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 198,148 shares of the biotechnology company's stock valued at $262,000 after buying an additional 8,954 shares during the period. 360 Financial Inc. increased its stake in shares of OPKO Health by 12.0% in the 2nd quarter. 360 Financial Inc. now owns 88,800 shares of the biotechnology company's stock valued at $117,000 after buying an additional 9,500 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of OPKO Health by 11.2% during the second quarter. The Manufacturers Life Insurance Company now owns 138,643 shares of the biotechnology company's stock worth $183,000 after acquiring an additional 13,912 shares during the last quarter. Finally, Oak Thistle LLC acquired a new position in shares of OPKO Health during the first quarter valued at $26,000. Institutional investors and hedge funds own 64.63% of the company's stock.
Analyst Ratings Changes
OPK has been the topic of several analyst reports. Wall Street Zen raised shares of OPKO Health from a "strong sell" rating to a "hold" rating in a report on Saturday, November 1st. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research report on Thursday, October 30th. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a research note on Thursday. They set a "neutral" rating on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research note on Wednesday, October 8th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $1.60 target price (down from $2.00) on shares of OPKO Health in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, OPKO Health has an average rating of "Hold" and an average target price of $2.28.
Read Our Latest Stock Analysis on OPK
OPKO Health Company Profile
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
